{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:51Z","timestamp":1788984831478,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01879-8","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:37:45Z","timestamp":1786081065000},"page":"4667-4682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spironolactone versus Bicalutamide for Female Pattern Hair Loss: A 24-Month Unicenter Retrospective Comparative Study of Effectiveness and Safety"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-0402","authenticated-orcid":false,"given":"Roc\u00edo","family":"Gil-Redondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jimenez-Cauhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Imbernon-Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Buend\u00eda-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Burgos Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"D\u00edaz-Guimaraens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Dom\u00ednguez-Santas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Hermosa-Gelbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saceda-Corralo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"1879_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2021.07.048","volume":"86","author":"JBF James","year":"2022","unstructured":"James JBF, Jamerson TA, Aguh C. Efficacy and safety profile of oral spironolactone use for androgenic alopecia: a systematic review. J Am Acad Dermatol. 2022;86:425\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1879_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamadermatol.2024.4593","volume":"161","author":"JM Fu","year":"2025","unstructured":"Fu JM, Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, et\u00a0al. Low-dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement. JAMA Dermatol. 2025;161(1):87\u201395.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1879_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaad.2020.03.087","volume":"83","author":"LJ Burns","year":"2020","unstructured":"Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol. 2020;83(1):276\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1879_CR4","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1111\/jocd.14773","volume":"21","author":"RdeM Carvalho","year":"2022","unstructured":"Carvalho RdeM, Santos LDN, Ramos PM, Machado CJ, Acioly P, Frattini SC, et\u00a0al. Bicalutamide and the new perspectives for female pattern hair loss treatment: what dermatologists should know. J Cosmet Dermatol. 2022;21(10):4171\u20135.","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"1879_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.det.2010.03.011","volume":"28","author":"D Rathnayake","year":"2010","unstructured":"Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28(3):611\u20138.","journal-title":"Dermatol Clin"},{"issue":"5","key":"1879_CR6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaad.2022.01.010","volume":"87","author":"J Plante","year":"2022","unstructured":"Plante J, Robinson I, Elston D. The need for potassium monitoring in women on spironolactone for dermatologic conditions. J Am Acad Dermatol. 2022;87(5):1097\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1879_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/CCID.S398950","volume":"16","author":"C Wang","year":"2023","unstructured":"Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W. The efficacy and safety of oral and topical spironolactone in androgenetic alopecia treatment: a systematic review. Clin Cosmet Investig Dermatol. 2023;16:603\u201312.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"8","key":"1879_CR8","first-page":"e43559","volume":"15","author":"M Aleissa","year":"2023","unstructured":"Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus. 2023;15(8):e43559.","journal-title":"Cureus."},{"issue":"5","key":"1879_CR9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jaad.2020.03.034","volume":"83","author":"FF Ismail","year":"2020","unstructured":"Ismail FF, Meah N, Trindade de Carvalho L, Bhoyrul B, Wall D, Sinclair R. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020;83(5):1478\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1879_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/17425255.2025.2461483","volume":"21","author":"JA Valdez-Zertuche","year":"2025","unstructured":"Valdez-Zertuche JA, Ram\u00edrez-Mar\u00edn HA, Tosti A. Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review. Expert Opin Drug Metab Toxicol. 2025;21(4):347\u201371.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"1879_CR11","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/j.jaad.2020.04.054","volume":"83","author":"D Fernandez-Nieto","year":"2020","unstructured":"Fernandez-Nieto D, Saceda-Corralo D, Jimenez-Cauhe J, Moreno-Arrones OM, Rodrigues-Barata R, Hermosa-Gelbard A, et\u00a0al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss. J Am Acad Dermatol. 2020;83(5):e355\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1879_CR12","doi-asserted-by":"publisher","first-page":"e13096","DOI":"10.1111\/dth.13096","volume":"32","author":"D Fernandez-Nieto","year":"2019","unstructured":"Fernandez-Nieto D, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones O, Jimenez-Cauhe J, et\u00a0al. Oral bicalutamide for female pattern hair loss: a pilot study. Dermatol Ther. 2019;32(6):e13096.","journal-title":"Dermatol Ther"},{"key":"1879_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdrv.2025.03.005","volume":"4","author":"SM Perez","year":"2025","unstructured":"Perez SM, Nguyen B, Senna MM. Efficacy and safety of bicalutamide in female hair loss: a review of the literature. JAAD Reviews. 2025;4:61\u20138.","journal-title":"JAAD Reviews"},{"issue":"5","key":"1879_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ajd.14306","volume":"65","author":"AK Jha","year":"2024","unstructured":"Jha AK, Zeeshan MD, Singh A, Singh AK. Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: a retrospective comparative study. Australas J Dermatol. 2024;65(5):437\u201343.","journal-title":"Australas J Dermatol"},{"issue":"12","key":"1879_CR15","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.1111\/jocd.14936","volume":"21","author":"RM Tr\u00fceb","year":"2022","unstructured":"Tr\u00fceb RM, Luu NNC, Uribe NC, R\u00e9gnier A. Comment on: Bicalutamide and the new perspectives for female pattern hair loss treatment: what dermatologists should know. J Cosmet Dermatol. 2022;21(12):7200\u20131.","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"1879_CR16","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jaad.2022.01.054","volume":"87","author":"RM Tr\u00fceb","year":"2022","unstructured":"Tr\u00fceb RM, Luu NNC, Rezende HD. Comment on \u201cBicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: a retrospective review of 35 patients.\u201d J Am Acad Dermatol. 2022;87(1):e29-30.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1879_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000227","volume":"11","author":"P Werachattawatchai","year":"2025","unstructured":"Werachattawatchai P, Khunkhet S, Harnchoowong S, Lertphanichkul C. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study. Int J Womens Dermatol. 2025;11(3):e227.","journal-title":"Int J Womens Dermatol"},{"key":"1879_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jdin.2024.12.002","volume":"19","author":"RdaS Lib\u00f3rio","year":"2025","unstructured":"Lib\u00f3rio RdaS, Motta AVda, Miot HA, M\u00fcller Ramos P. Bicalutamide 25 mg combined with minoxidil 1 mg versus minoxidil 1 mg for female pattern hair loss: a randomized double-blind clinical trial. JAAD Int. 2025;19:48\u201355.","journal-title":"JAAD Int"},{"key":"1879_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jdin.2025.07.008","volume":"23","author":"R Gil-Redondo","year":"2025","unstructured":"Gil-Redondo R, Saceda-Corralo D, Jim\u00e9nez-Cahu\u00e9 J, Va\u00f1\u00f3-Galv\u00e1n S. Improvement of female pattern hair loss with bicalutamide: a time-dependent process. JAAD Int. 2025;23:46\u20137.","journal-title":"JAAD Int"},{"issue":"1","key":"1879_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/ijd.13838","volume":"57","author":"RD Sinclair","year":"2018","unstructured":"Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104\u20139.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1879_CR21","first-page":"e91","volume":"23","author":"S Devjani","year":"2024","unstructured":"Devjani S, Ezemma O, Jothishankar B, Saberi S, Kelley KJ, Senna MM. Efficacy of low-dose spironolactone for hair loss in women. J Drugs Dermatol. 2024;23(3):e91\u20132.","journal-title":"J Drugs Dermatol"},{"key":"1879_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03361-x","author":"DD Desai","year":"2024","unstructured":"Desai DD, Nohria A, Sikora M, Anyanwu N, Shapiro J, Lo Sicco KI. Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. Arch Dermatol Res. 2024. https:\/\/doi.org\/10.1007\/s00403-024-03361-x.","journal-title":"Arch Dermatol Res"},{"key":"1879_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jdin.2024.07.023","volume":"17","author":"A Nohria","year":"2024","unstructured":"Nohria A, Desai D, Sikora M, Anyanwu N, Caplan A, Shapiro J, et\u00a0al. Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: a retrospective review. JAAD Int. 2024;17:24\u20136.","journal-title":"JAAD Int"},{"issue":"6","key":"1879_CR24","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jaad.2020.10.097","volume":"84","author":"B Olamiju","year":"2021","unstructured":"Olamiju B, Craiglow BG. Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls. J Am Acad Dermatol. 2021;84(6):1689\u201391.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1879_CR25","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaad.2025.01.056","volume":"92","author":"N Yoong","year":"2025","unstructured":"Yoong N, Yii V, Sinclair R, Bhoyrul B. Combination of oral minoxidil and bicalutamide for the treatment of female pattern hair loss in adolescents. J Am Acad Dermatol. 2025;92(5):1156\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1879_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.09.082","author":"J Kantor","year":"2025","unstructured":"Kantor J. Highlights from JAAD International: December 2025. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.082.","journal-title":"J Am Acad Dermatol"},{"key":"1879_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1556705","author":"C Liu","year":"2025","unstructured":"Liu C, Liu X, Shi T, Wang Y, Sui C, Zhang W, et\u00a0al. Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1556705.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1879_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaad.2021.10.048","volume":"87","author":"A Moussa","year":"2022","unstructured":"Moussa A, Kazmi A, Bokhari L, Sinclair RD. Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: a retrospective review of 35 patients. J Am Acad Dermatol. 2022;87(2):488\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"1879_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03261-0","author":"A Nohria","year":"2024","unstructured":"Nohria A, Desai D, Sikora M, Mandal S, Caplan A, Shapiro J, et\u00a0al. To evaluate hypertrichosis with low dose oral minoxidil and spironolactone combination therapy for alopecia. Arch Dermatol Res. 2024. https:\/\/doi.org\/10.1007\/s00403-024-03261-0.","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01879-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01879-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01879-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:32Z","timestamp":1788981692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01879-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1879"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01879-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roc\u00edo Gil-Redondo declares receiving honoraria from Eli Lilly, Pfizer, UCB and Cantabria Labs as a speaker. Adrian Imbernon-Moya declares receiving honoraria from Novartis, Lilly, UCB Pharma, LEO Pharma, Janssen, Abbvie and Almirall as a speaker. Juan Jim\u00e9nez-Cahu\u00e9 declares receiving honoraria from Eli Lilly, Amgen, Almirall and Cantabria Labs as a speaker. David Saceda-Corralo declares receiving honoraria from Pfizer, Eli Lilly, and Cantabria Labs as a speaker and advisor. Dr David Saceda-Corralo is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Dr Saceda-Corralo was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Sergio Va\u00f1\u00f3-Galv\u00e1n declares receiving honoraria from Pfizer, Eli Lilly, Pierre Fabre, and Cantabria Labs as a speaker and advisor. All conflicts of interest are unrelated to the submitted work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical considerations were strictly adhered to throughout the study. Consent for the publication of recognizable patient photographs or other identifiable material was obtained by the authors and included at the time of article submission to the journal stating that all patients gave consent with the understanding that this information may be publicly available. This study was reviewed and approved by the Institutional Review Board of Hospital Universitario Ram\u00f3n y Cajal (DER-AGA 01-2019).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}